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Abstract
Background:  Depending on the population studied, large genomic rearrangements (LGRs) of the
mismatch repair (MMR) genes constitute various proportions of the germline mutations that predispose
to hereditary non-polyposis colorectal cancer (HNPCC). It has been reported that loss of heterozygosity
(LOH) at the LGR region occurs through a gene conversion mechanism in tumors from MLH1/MSH2
deletion carriers; however, the converted tracts were delineated only by extragenic microsatellite
markers. We sought to determine the frequency of LGRs in Slovak HNPCC patients and to study LOH
in tumors from LGR carriers at the LGR region, as well as at other heterozygous markers within the gene
to more precisely define conversion tracts.
Methods: The main MMR genes responsible for HNPCC, MLH1, MSH2, MSH6, and PMS2, were analyzed
by MLPA (multiplex ligation-dependent probe amplification) in a total of 37 unrelated HNPCC-suspected
patients whose MLH1/MSH2 genes gave negative results in previous sequencing experiments. An LOH
study was performed on six tumors from LGR carriers by combining MLPA to assess LOH at LGR regions
and sequencing to examine LOH at 28 SNP markers from the MLH1 and MSH2 genes.
Results: We found six rearrangements in the MSH2 gene (five deletions and dup5-6), and one aberration
in the MLH1 gene (del5-6). The MSH2 deletions were of three types (del1, del1-3, del1-7). We detected
LOH at the LGR region in the single MLH1 case, which was determined in a previous study to be LOH-
negative in the intragenic D3S1611 marker. Three tumors displayed LOH of at least one SNP marker,
including two cases that were LOH-negative at the LGR region.
Conclusion: LGRs accounted for 25% of germline MMR mutations identified in 28 Slovakian HNPCC
families. A high frequency of LGRs among the MSH2 mutations provides a rationale for a MLPA screening
of the Slovakian HNPCC families prior scanning by DNA sequencing. LOH at part of the informative loci
confined to the MLH1 or MSH2 gene (heterozygous LGR region, SNP, or microsatellite) is a novel finding
and can be regarded as a partial LOH. The conversion begins within the gene, and the details of conversion
tracts are discussed for each case.
Published: 20 November 2009
BMC Cancer 2009, 9:405 doi:10.1186/1471-2407-9-405
Received: 9 April 2009
Accepted: 20 November 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/405
© 2009 Zavodna et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
Page 2 of 15
(page number not for citation purposes)
Background
Hereditary non-polyposis colorectal cancer, HNPCC (also
known as Lynch syndrome), is a frequent, autosomal,
dominantly-inherited predisposition mainly for early-
onset of colorectal and endometrial cancers, and less fre-
quently for other type of malignancies [1]. The clinical
definition of HNPCC diagnosis is based largely on the
Amsterdam criteria (AC), which were set up in 1991 with
the purpose of selecting families for mutational screening
of mismatch repair (MMR) genes, whose germline patho-
genic mutations cause this condition [2,3]. The less strin-
gent Bethesda guidelines (BG), and later, the Revised
Bethesda Guidelines (RBG) were established to identify
additional HNPCC patients that do not fulfill the strict
Amsterdam criteria [4]. The examination of tumor tissue
of HNPCC-suspected patients for the presence of micros-
atellite instability (MSI) and/or alterations in the MMR
protein expression patterns may be also useful in pre-
selecting patients for mutational screening. Nevertheless,
a precise distinction between familial and sporadic MMR
deficient tumors before mutational screening still remains
a complex issue [5] and not all of the clinico-genetical or
tumor characteristics may be available for each case.
Identification of the predisposing germline mutation is
important because it confirms the clinical diagnosis of
HNPCC and enables targeted clinical surveillance, which
significantly reduces cancer morbidity and mortality in
Lynch syndrome families [6]. Taking into account the
number of potentially mutated MMR  genes (MLH1,
MSH2, MSH6, PMS2, PMS1, MLH3) and different types of
mutations, the screening approaches are very complex
and involve many techniques. Despite the tremendous
advances in molecular diagnosis of HNPCC that have
been made since the discovery of genetic clues of this dis-
ease, the genetic etiology of many clinically defined
HNPCC patients remains unsolved because of technical
limitations and/or difficulties in confirming the patho-
genicity of identified gene alterations [7].
Inherited large genomic rearrangements (LGRs) in the
MMR  genes, which are not detectable by commonly
applied DNA sequencing, became a subject of numerous
HNPCC studies in recent years. One of the goals of these
studies was to determine the frequency of these mutations
in HNPCC patients. Although direct comparisons of fre-
quencies determined in the different studies are not pos-
sible due to variability in the way the cohorts were
selected, it seems that in some populations, LGRs are
more frequent than in others. LGRs are reported to com-
prise 10% to 55% of all MMR gene mutations, and most
occur in major MMR  genes; i.e. the MLH1  and MSH2
genes [8-17]. An exceptionally low frequency of LGRs in
these two genes (<1.5%) was reported in a study of the
Spanish population [18], though a higher frequency of
LGRs was found in a Basque Country population [19].
The frequency of LGRs may be remarkably higher in cer-
tain populations due to founder effects [9,10,19-24].
There is no consensus on how to select patients for LGR-
screening. In many studies, the patients who were previ-
ously screened by conventional screening/scanning meth-
ods (DGGE, HDA, DHPLC, DNA sequencing), and in
whom no germline mutation could be found, are ana-
lyzed for the presence of LGR [25]. However, the examina-
tion of LGR prior to the laborious exon-by exon mutation
scanning of the MMR genes has also been suggested and
is feasible by applying simple and robust techniques, such
as MLPA (multiplex ligation-probe dependent amplifica-
tion) [18]. Knowing the frequency of LGR in the popula-
tion can significantly influence the screening algorithms
for patients at risk for HNPCC.
Contrary to the germline LGRs, somatic LGRs in the MMR
genes, which represent potential MMR inactivating events
referred to as second hits during tumorigenesis, are rarely
studied. The heterozygous LGR region present in the
germline DNA can be used as a marker to study loss of het-
erozygosity (LOH) in the corresponding tumor DNA. One
study showed that tumors of the MLH1/MSH2 germline
LGR carriers often display a somatic mutation identical to
one that is present in the germline DNA [1]. Furthermore,
LOH analyses of these tumors using microsatellite mark-
ers flanking the respective gene have revealed that loss of
the wild-type allele predominantly occurs through gene
conversion, rather than mitotic recombination or physical
deletion of the respective gene locus. Although in general,
little is known about gene-conversion events that occur in
cancer [26], it is likely that the conversion tracts do not
encompass a whole sequence of the MLH1 or MSH2 gene
in the LOH-positive cases. These two genes carry a number
of single nucleotide polymorphisms (SNPs) that can be
potentially utilized to delineate the conversion tracts
more precisely than is possible using the extragenic micro-
satellite markers. The SNP markers, though less hetero-
zygous than the microsatellite markers, have been proven
to be useful in detecting LOH at MMR loci [27,28]. In
their recent LOH study on the heterogeneously defined
microsatellite unstable carcinomas, van Puijenbroek et al
[29] used SNP arrays to assess LOH on a genome-wide
level. Although, such commercial arrays are very attractive
for LOH studies, they probably would not involve suffi-
cient numbers of SNPs located within the MMR genes to
enable a very detailed LOH study in the MMR gene of the
LGR carriers.
To date, among 58 clinically well-defined Slovak HNPCC
families, 21 clearly pathogenic MMR gene mutations have
been identified by applying direct DNA genomic sequenc-
ing [30,31]. As DNA sequencing fails to detect LGRs, it is
possible that in some of these patients, an LGR is respon-BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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sible for HNPCC. In the presented study, we used the
MLPA technique to screen for LGRs in the MMR genes for
the first time in the Slovak population. As a second step,
we studied potential LOH events in those patients in
whom the LGR was detected in the germline, by combin-
ing MLPA and DNA sequencing at the intragenic MLH1/
MSH2-SNP markers.
Methods
Patients and samples
This study included a total of 37 Slovak CRC patients
investigated for the presence of LGR in the MMR genes.
Eleven of these patients were enrolled in our previous
study [32] while remaining 26 cases from cohort repre-
sented new patients referred to National Cancer Institute
for genetic counselling after 2005. In summary, the
patients were corresponding to: (a) 17 index cases of unre-
lated families that satisfied Amsterdam criteria I or II for
HNPCC; (b) 20 unrelated index cases that satisfied
Bethesda guidelines or Revised Bethesda Guidelines. The
tumor specimens of 20 patients were tested for MSI (10
previously and other 10 in this study) and 18 could be
analyzed for MMR protein expression by IHC (6 before
and 12 now). In summary, at least one of these assays has
been performed for each of 23 patients. MSI analyses in
the current study were performed using new MSI Analysis
System, Version 1.1 (Promega Co, Madison, WI), and the
expression pattern of four MMR proteins (MLH1, MSH2,
MSH6, and PMS2) was analyzed by standard IHC tech-
niques as previously [33]. Because no pathogenic germ-
line mutations could be detected by conventional
mutation detection techniques (DGGE and/or sequenc-
ing) in the cohort, the patients were investigated for the
presence of LGRs in their germline by MLPA (next sec-
tion). Written informed consent was obtained from all
patients included in this study. The study has been
approved by The Ethics Committee of National Cancer
Institute in Bratislava, and has been performed in accord-
ance with the Declaration of Helsinki.
LGR-screening and MLPA-based LOH analyses
DNA was isolated by either Qiagen QIAamp DNA Blood
Mini kit (Qiagen, Hilden, Germany) or Recover All™ Total
Nucleic Acid Isolation Kit (Applied Biosystems, Foster
City, CA), depending on the source of material. For detec-
tion of aberrant exon(s) copy numbers in constitutional
DNA, we used the SALSA MLPA kits MSH2/MLH1 (P003,
version sold until 2006) and PMS2/MSH6 (P008) (MRC
Holland, Amsterdam, The Netherlands) [34]. For MLPA-
based LOH analyses in tumor DNA of MLH1/MSH2 LGR
carriers, we used the P003 kit. After PCR amplification
with 6-FAM-labeled primers, the samples were analyzed
with an ABI 310 sequencer using GeneMapper software v
3.7 (Applied Biosystems, Inc., Foster City, CA). Specific
peaks corresponding to each exon were identified accord-
ing to their migration relative to the size standards and
analyzed by MLPA-Excel spreadsheets for copy number
changes. Dosage quotients equal to 0.5 (SD ≤ 20%) were
considered deleted and dosage quotients 1.5 (SD ≤ 20%)
duplicated. MLPA assay has been used for LOH detection
by utilizing a heterozygous LGR region as a marker for
LOH, similarly as described before [1,34,35], however
LOH was calculated by using a formula: exon dosage quo-
tient in the tumor DNA/exon dosage quotient in the
germline DNA, that was applied on the exons affected in
the germline. A value ≤ 0.5 indicated LOH at the site of
large deletion and a value ≥ 1.5 would indicate an LOH of
the region duplicated in the germline. The identified
exon(s) copy number changes were confirmed in at least
two independent MLPA reactions.
SNP-based LOH analyses using DNA sequencing
The SNPs listed in Table 1 (n = 28) were analyzed by flu-
orescent capillary DNA sequencing. More SNPs (n = 18)
were assessed for the MSH2 gene than for the MLH1 gene
(n = 10), in order to cover large intronic regions in the
central part (introns 6-8), as well as distal regions of the
MSH2 gene. The sequences of the PCR primers used for
the amplification of the regions containing SNP markers
are provided in Table 2. The SNPs were visualized on an
ABI PRISM 310 Genetic Analyzer. DNA sequencing at het-
erozygous SNP markers has been utilized for the evalua-
tion of LOH, similarly as described previously [36,37],
however for LOH assessment we used similar formula
generally accepted for LOH determination by the micros-
atellite markers:
The alleles with higher intensity of signal were set for N1 
(in normal DNA) or T1 (in tumor DNA) while the alleles 
with lower intensity of signal were set for N2 (in normal 
DNA) or T2 (in tumor DNA), and ratios ≤ 0.5 implied the 
presence of LOH at the respective SNP marker.
The definition of partial LOH
The concurrent retention of heterozygosity of at least one
marker and loss of heterozygosity of at least one other
marker within the gene.
Results
Screening of the LGRs in the germline DNA
The cohort of 37 index patients at risk for HNPCC
screened in this study for LGRs has been established
mainly on the basis of clinico-genetical criteria for
HNPCC (AC-I and II, BG and RBG) and a lack of a germ-
line mutation in the major MMR genes (MLH1  and
LOH =
height of normal allele two (N2)
height of normal allele e one (N1)
height of tumor allele two (T2)
height of tumor a allele one (T1)BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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MSH2) by conventional mutation screening techniques.
Eleven of these patients were extensively described in our
previous study; the tumor specimens of 10 of them were
analyzed by MSI assay in which 8 and 2 showed MSI-H
and MSI-L status, respectively [32]. In the same study, 6
tumors were analyzed by IHC in which 2 analyses failed
due to fixation problem and from 4 successfully stained
tumors, 3 had a loss of MSH2 expression while one was
MLH1 negative [32]. From 26 new cases, the tumor spec-
imens of 10 of them were analyzed by MSI assay in which
9 and one showed MSI-H and MSI-L status, respectively.
Figure 1 shows the representative pictures from these anal-
yses. We have not included patients with stable tumors
(MSS) in the study, however the MSI status for 17 cases
from our cohort could not be analyzed because of no
availability of fresh or FFPE tumor tissue. Figure 2 shows
the representative pictures from IHC analyses. Twelve
tumors were stained; 1 analysis failed due to fixation
problem and from remaining 11 successfully stained
tumors, 3 showed loss of MSH2 expression while eight
were MLH1 negative. Because no pathogenic germline
mutations could be detected by conventional mutation
detection techniques in cohort, the patients were sub-
jected to LGR screening by MLPA. In total, 7 LGRs were
identified, all of which were detected using the SALSA
MLPA kit P003 MSH2/MLH1. No deletions or duplica-
tions at the exons of other MMR  genes detectable by
SALSA MLPA kit P008 were observed (all exons of MSH6
and PMS2, and some exons of MLH1, MLH3 and MSH3).
The clinico-pathological features of the LGR carriers and
descriptions of identified changes are summarized in
Table 3. Only one LGR was found in the MLH1 gene (in
the patient SK-22)- a deletion of exons 5 and 6. LGRs
found in the MSH2 gene represented a single duplication
of exons 5 and 6 (SK-20 case) and three different types of
deletions in five patients: an exon 1 deletion (SK-23), a
deletion of exons 1-3 (SK-21 and SK-28), and a deletion
of exons 1-7 (SK-14 and SK-25). Most patients with
detected LGRs (5/7) fulfilled strict Amsterdam criteria for
HNPCC. The two remaining LGR carriers complied with
the less stringent Bethesda Guidelines. The average age of
the LGR carriers at diagnosis was 38 years and three of
them suffered from synchronous cancers. The MSI status
of the tumors of five LGR carriers was known from our
previous study [32]. These were SK-14, SK-20, SK-21, SK-
22 with MSI-H tumors, and SK-23 who had low-level MSI
cancer. The tumor tissue of the SK-25 case was not availa-
ble for MSI analysis, however MSI-H status in the tumor
of SK-28 patient was determined in recent study. The
absence of MSH2 protein in tumors of the SK-20 and SK-
21 cases, and a loss of the MLH1 protein expression in the
SK-22 tumor detected by the IHC evaluation of tumor sec-
tions previously was in agreement with MLPA findings in
this study. The mutations identified in five index patients
were also present in 7 out of 10 tested relatives.
Further characterization of identified LGRs
In the MLPA assay, mutations and/or polymorphisms that
are very close to the probe ligation site may also result in
a reduced relative peak area. Therefore, deletions detected
by a single probe (single exon deletions) always require
confirmation. In order to confirm MSH2 deletion of exon
1 in the SK-23 case, we used the SALSA MLPA kit P008
PMS2/MSH6 including a single probe to MSH2 exon 1,
different from the exon 1 probe present in the SALSA
MLPA kit MSH2/MLH1 (P003). We again observed a
reduction of peak area at exon 1 in the SK-23 case using
the second kit, thus confirming the presence of this single
exon deletion. The remaining four cases carrying multi-
exonic MSH2 deletions involving exon 1 also displayed a
reduction of peak area at the probe for MSH2 exon 1. In
addition (as shown in Table 3), three patients exhibited
an aberrant hybridization signal for one or two probes,
Table 1: SNP-based LOH markers used in this study.
Gene SNPa location dbSNP reference IDb
MLH1 c.1-93G>A Promoter rs1800734
c.453+79A>G Intron5 rs4234259
c.655A>G [p.I219V] Exon8 rs1799977
c.790+955C>A Intron9 rs1558528
c.791-1406C>T Intron9 rs4647269
c.791-488A>G Intron9 rs4647277
c.1038+86T>C Intron11 rs2286939
c.1039-78A>G Intron11 rs11129748
c.1668-19A>G Intron14 rs9876116
c.1990-121C>T Intron17 rs2241031
MSH2 c.1076+1681G>T Intron6 rs10191478
c.1077-80G>A Intron6 rs2347794
c.1276+1349T>A Intron7 rs3771272
c.1276+1394A>T Intron7 rs3771273
c.1277-212T>A Intron7 rs1981928
c.1277-118G>A Intron7 rs1981929
c.1386+719T>C Intron8 rs7602094
c.1387-914A>G Intron8 rs6711675
c.1511-91G>T Intron9 rs3732182
c.1511-9A>T Intron9 rs12998837
c.1661+12G>A Intron10 rs3732183
c.1759+107A>G Intron11 rs3764959
c.1759+183G>A Intron11 rs3764960
c.1760-1207C>T Intron11 rs3821227
c.2006-6T>C Intron12 rs2303428
c.2210+175G>A Intron13 rs4583514
c.2210+274T>G Intron13 rs4608577
c.2635-214T>C Intron15 rs2042649
a SNP nomenclature reflecting the recommendations of Human 
Genome Variation Society; bAccording to the dbSNP at http://
www.ncbi.nlm.nih.gov/SNP/index.html. For the determination of SNP 
location, the cDNA sequence alignements have been performed using 
NCBI RefSeq NM_000249.2 with genomic contigs NT_005580.6 and 
NT_022517.17 for the MLH1, and NM_000251.2 with genomic contig 
NT_022184.14 for the MSH2 gene.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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which were confined to the TACSTD1  gene located
upstream of MSH2.
LOH analyses in tumors from LGR carriers
Six tumors from different LGR carriers were available for
LOH analyses. MLPA revealed a somatic copy deletion
identical to the germline deletion (MLH1 del5-6) in the
SK-22 tumor (Figure 3B, C). Other tumors did not exhibit
LOH at the heterozygous LGR region (two examples are
shown on Figure 3D, E and 3F, G). Interestingly, as in the
case of LOH at the LGR (SK-22), in the previous studies
from our laboratory we have seen a retention of heterozy-
gosity at intragenic microsatellite marker D3S1611
located in MLH1 intron 12 [32,38] [see additional file 1].
The case of retention of heterozygosity at one informative
marker with a loss of heterozygosity at another informa-
tive marker within the same gene was subsequently
termed 'partial LOH'. The observation of partial LOH in
the MLH1 gene in the SK-22 tumor led us to search for
SNP markers that are heterozygous/informative in our
samples and enable a detailed examination of LOH
within the mutated MLH1 or MSH2 gene. By testing the
SNP markers listed in Table 1, we detected additional
LOH events in three tumors. Germline DNA of the SK-22
case was heterozygous at the c.1-93G>A locus located in
the promoter of the MLH1 gene and displayed LOH at this
SNP (Figure 4E and 4F), indicating that the conversion
covered not only the LGR region but also the region
upstream of the LGR. The remaining two cases, neither of
which showed LOH at the LGR region, exhibited LOH at
the informative SNP markers (Figure 4A-D). The tumor of
the SK-14 patient, which retained heterozygosity at MSH2
del1-7, displayed LOH at four SNPs (c.1511-91G>T and
c.1511-9A>T in intron 9, c.1661+12G>A in intron 10, and
c.1759+107A>G in intron 11), indicating the presence of
a partial LOH located downstream of the LGR region.
Germline DNA of the SK-20 patient was heterozygous at
the c.1277-118G>A locus in intron 7 and showed LOH at
this SNP. We had previously detected LOH by SNaPshot
in the same case at two MSH2-SNPs located in intron 1
Table 2: Primers for amplification of the fragments containing SNP markers.
SNP Forward primer sequence (5' → 3') Reverse primer sequence (5' → 3') bpa
Gene MLH1
c.1- 93G>A CAACCCACAGAGTTGAGAAATTT GCTCAACGGAAGTGCCTT 152
c.453+79A>G TGGAAAACTGAAAGCCCC TTAGAGGATATCTTGGGACCTCC 201
c.655A>G CGTGGACAATATTCGCTCC CTAAAGCAAACTCTTAACACACATAATATC 156
c.790+955C>A CCAGCTGTAAATGTTTCAAAATAT AACATTTTCTGAGCCTTGATTAAA 200
c.791- 1406C>T CAGAGTACAGTGACATTAATGAT TCTCTCTGAACAGATTTAGATGA 183
c.791- 488A>G TGATACCATTTCTGTGCCATTTT GGCCAGCACTATTATAGACGT 157
c.1038+86T>C GTCAGGGCGCTTCTCATC GGAACAACAGCACAATACCTT 173
c.1039- 78A>G ATAATTTTAAGATTATAAGGATTTTG GTGGAGAGACTCAGAATAAGA 186
c.1668- 19A>G ACAGCCAGGCAGAACTATTTC TGAGTATCTGGTAGAACAGTTCTTC 153
c.1990- 121C>T CCTGCTCTCATCCCCACT ACCTGGTCCAAAGAAATTCA 178
Gene MSH2
c.1076+1681G>T AACGATATTGGAATGATTGGATC ACTTGCAAATTACCCAGTCCTT 177
c.1077- 80G>A AAATGGAATTTTGAGCTGATTT ATCTTCTACAAAAGCTTCCACTAA 134
c.1276+1349T>A GTTGTTATGTCTAATACATAAAGC TCAAAACGTATGTTTTAATGGTTC 157
c.1276+1394A>T GTTGTTATGTCTAATACATAAAGC TCAAAACGTATGTTTTAATGGTTC 157
c.1277- 212T>A CATGTTTCTGCATCTATATTACTT TAAACAAGCATCATTTGATCCAAA 201
c.1277- 118G>A CATGTTTCTGCATCTATATTACTT TAAACAAGCATCATTTGATCCAAA 201
c.1386+719T>C TCAGTCTTAGCCTCCCAAAAT CGACAACTATTTAGGAGATGCA 131
c.1387- 914A>G AGTCTCAGTATGTCACCTAGG TAGCAGTGCGCACCTGTAGT 131
c.1511- 91G>T CAAGTAAGTAGTATTTGAATCTTTTCTG GCACTGGAATCCAGTTTAATCT 202
c.1511- 9A>T CAAGTAAGTAGTATTTGAATCTTTTCTG GCACTGGAATCCAGTTTAATCT 202
c.1661+12G>A TCCAGAAGAATGGTGTTAAATTT TTAGTAAAACTTATCATAGAACATTCAC 120
c.1759+107A>G GGCTTTTGGTAACAGAAGAAAAA CTGCCATTTTTTGTTTCTATGTG 176
c.1759+183G>A GGCTTTTGGTAACAGAAGAAAAA CTGCCATTTTTTGTTTCTATGTG 176
c.1760- 1207C>T TAATTAGGTCTGCTTGGCCATT CAGAACATTCAAGATAAAAGCATT 166
c.2006- 6T>C ACATCTTTGGGCAGGCTG CCATGAGTACTATCACCCCA 214
c.2210+175G>A GTCTTAGTTTAATAGTTGTTTTCC ATTCCAGGAAGTGTGAACAGT 198
c.2210+274T>G GTCTTAGTTTAATAGTTGTTTTCC ATTCCAGGAAGTGTGAACAGT 198
c.2635- 214T>C CCAGTATTCTTTGTAAACCTTGA GTCTCAAACTCCTCCCACATT 156
a size of amplicon in base pairs (bp); Note: several SNPs are located on the same ampliconBMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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(c.211+9C>G, c.211+98T>C), which are difficult to
sequence due to formation of secondary structures in the
respective regions [28]. Taken together, two distinct LOH
events interrupted by heterozygous dup5-6 (tandem
arrangement assumed) are apparently present in the
tumor of the SK-20 patient. In two cases (SK-21 and SK-
23), no LOH was detected at any informative SNP, and
the SK-28 germline DNA was SNP-uninformative. It has
to be noted that for LOH measurements of each patient
sample pair of normal and tumor tissue, the same tumor
DNA isolation samples were analyzed in different assays
taking in account of tumor heterogeneity, including the
case SK-22 analyzed in a different time in a different study
by microsatellite marker D3S1611. All data used for LOH
analyses by MLPA and SNP markers together with calcu-
lated LOH ratios are summarized in additional files 2 and
3. There was no apparent difference of the clinico-patho-
logical characteristics between the tumors with partial
LOH (SK-14, SK-20, SK-22) and tumors without LOH
(SK-21, SK-23).
Discussion
The index cases of 37 families included in this study were
analyzed for LGRs in the MMR genes using two MLPA kits,
and 7 (19%) were found to have this type of alteration.
Taking into account all mutations identified so far (28
mutations in total), including the mutations found in this
study, the LGRs account for 25% of clearly pathogenic
changes in MMR genes from Slovakian HNPCC families.
The large deletion in the MLH1 gene, a del5-6, has not
been reported in other populations and, as a single muta-
tion, represents only 6.7% (1 of 15) of all MLH1 muta-
tions, while LGRs in the MSH2 gene account for 50% (6
of 12) of all MSH2 mutation-positive cases [30-32] (one
family with inherited MSH6 mutation is unpublished).
Although large duplications in MMR genes seem to occur
much less frequently than deletions [18,39-43], we
uncovered one duplication of exons 5 and 6 affecting the
MSH2 gene in our relatively small cohort. A duplication
of these two exons in the MSH2 gene has been reported
[14].
Our results provide the first evidence that, like in many
other studied populations, large genomic changes in the
MLH1/MSH2 genes exist in Slovakian HNPCC families. In
addition, this type of mutation is frequent, particularly in
the  MSH2  gene, implying that the mutation screening
algorithm should begin with MLPA and not with DNA
sequencing, especially in cases where the protein expres-
sion pattern of the tumor shows a loss of MSH2 protein or
is unknown. For cases that lack detectable MLH1 protein
expression in tumors analyzed by IHC, DNA sequencing
of the MLH1 gene prior MLPA screening is more appropri-
ate. LGR correlated strongly with MSI-H status; more than
83% tumors of LGR carriers displayed MSI-H. However,
also high rate of AC-I patients with MSI-L tumors may be
potentially LGR carriers (in our cohort ~33%). For
patients with no FFPE tissue available for MSI analysis
such as the case SK-25 in our study, MLPA assay may be
considered if the patient fulfills strict AC criteria. Simi-
Table 3: Germline LGRs identified in Slovakian HNPCC families.
Family code HNPCC 
criteria
Tumor localization
(age at diagnosis)
Gene Deleted or 
duplicated exons
(systematic 
nomenclature)
5' deletion MSI IHC LOH
SK-14 AC-I ascendens + sigmoid 
colon (27)
MSH2 del1-7 
(c.1-?_1276+?del)
15 kb MSI-H * partial
SK-20 AC-II sigmoid colon (36) MSH2 dup5-6 
(c.793-?_1076+?dup)
n.a. MSI-H MLH1+, MSH2- partial
SK-21 BG cecum (27) MSH2 del1-3 
(c.1-?_645+?del)
15 kb and 27 kb MSI-H MLH1+, MSH2- none
SK-22 AC-I sigmoid colon (36) MLH1 del5-6 
(c.381-?_545+?del)
n.a. MSI-H MLH1-, MSH2+ partial
SK-23 AC-I cecum + ascendens 
colon (53)
MSH2 del1 (c.1-?_211+?del) - MSI-L * none
SK-25 AC-I cecum (42) MSH2 del1-7 
(c.1-?_1276+?del)
15 kb # #
SK-28 BG ascendens colon + 
rectum (48)
MSH2 del1-3 
(c.1-?_645+?del)
n.d. MSI-H * n.i.
Fulfillment of HNPCC criteria: AC-I, AC-II, Amsterdam criteria I, II; BG, Bethesda guidelines. Systematic nomenclature: According to the 
recommendations of the Human Genome Variant Society using reference sequences NM_000249.2 (MLH1) and NM_000251.1 (MSH2). 5' deletion: 
the probes detecting regions located 15 or 27 kb before MSH2 localized in the TACSTD1 gene; n.a., not applicable; - no reduction of the signal at any 
of the TACSTD1 probes, n.d., not determined; MSI, microsatellite instability analysis: MSI-H, high level of MSI; MSI-L, low level of MSI; IHC, 
immunohistochemical analysis, +, a positive staining, -, a negative staining, * staining failed due to fixation problem; #, no FFPE tissue available for 
analysis; LOH, loss of heterozygosity, n.i. not informative in any LOH markerBMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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larly, MMR gene expression results correlated with MLPA
findings, indicative of MSH2 and MLH1 mutation.
Similar to what has been found in other studies, there was
a high proportion 5/6 (83%) of deletions encompassing
exon 1 among the MSH2  rearrangements
[8,11,13,41,42,44,45]. Common origin, or founder effect,
cannot be excluded for deletions of exons 1-3 detected in
the patients, SK-21 and SK-28, and likewise of exons 1-7
identified in the patients, SK-14 and SK-25. The examina-
tion of haplotypes and/or breakpoints may help to deter-
mine whether this is the case. Unfortunately, the risk
haplotype could not be traced in the families due to the
small number of people available for examination. For
deletions encompassing exon 1, determination of break-
points by long range PCR is difficult given that 5' break-
points may be located up to 200 kb upstream of the MSH2
transcription initiation site [44]. However, according to
the preliminary results of the large on-going study to test
a new methodological approach for breakpoint detection
involving the LGR carriers of our work, the SK-14 and SK-
25 cases do seem to share common breakpoints (Dr.
Benno Röthlisberger, personal communication). For three
out of five MSH2 deletion cases (SK-14, SK-21, and SK-
25), we demonstrated that one breakpoint should lie in
the TACSTD1 gene, which is upstream of the MSH2 gene.
Current findings that some HNPCC patients carry aberra-
tions exclusively in the TACSTD1 gene leading to the gen-
eration of TACSTD1/MSH2 fusion transcripts [46,47] led
to the creation of a new version of the P003 kit (B1 ver-
sion), including TASCTD1 probes to enable simultaneous
MLPA analysis of this gene and the major MMR genes
(MLH1 and MSH2). Using the P008 kit (MSH6/PMS2) in
our cohort, we detected copy number changes for the
TASCTD1  gene only in conjunction with deletions of
exon(s) in the MSH2 gene.
Although based on a small number of cases, our cumula-
tive data from LOH analyses performed by various mark-
ers (heterozygous LGR region, SNPs, and microsatellites)
indicate that partial LOH can take place at the mutated
MLH1 or MSH2 loci in LGR carriers. We have adapted the
term 'partial LOH' from LOH studies conducted on the
chromosomal level, showing for instance partial LOH
MSI analysis Figure 1
MSI analysis. A: Normal DNA. B: Matching tumor DNA with MSI-H status. The presence of new alleles in the tumor sample 
(arrows) that were not present in the normal sample indicates microsatellite instability. The distribution of MSI markers and 
stable pentanucleotide markers is indicated in upper part of panel A.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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confined to one arm of a chromosome [48], and have
used this term to signify concurrent retention of heterozy-
gosity of at least one marker and loss of heterozygosity of
at least one other marker within the gene. At this point, it
is not clear whether partial LOH also occurs in HNPCC
tumors of individuals carrying other types of MMR gene
mutations, for instance point mutations. A varying fre-
quency of LOH has been described in the literature for the
MLH1 and MSH2 loci in the series of MMR gene mutation
carriers. LOH at the MLH1 locus has been reported in 35-
85% of all tumors with a germline mutation in the MLH1
gene [49-55]. LOH at the MSH2 locus has been described
in 14-50% of all tumors with a germline MSH2 mutation
[49,51,54,56]. Given that partial LOH may be not
detected when only a few markers are used, it is possible
that the importance of LOH events at MMR  genes in
HNPCC tumors is still underestimated.
Schematic representations of partial LOHs in both genes
are shown in Figure 5 and 6. The precise characterization
of gene conversion events through the determination of
initiating and terminating points is practically difficult;
thus, annotation of the converted tract usually represents
the minimal and maximal converted tracts (MinCT,
MaxCT) [26]. In the tumors we examined, the overall het-
erozygosity of SNP markers was unexpectedly low, and
thus allowed us to characterize converted tracts only par-
tially. The microsatellite markers flanking the MLH1 or
MSH2 gene that were tested in previous studies from our
laboratory [32,38] were also uninformative, due to the
presence of instability in these MMR deficient tumors.
The underlying mechanism for partial LOH is unclear at
the moment; however, it is likely that specific motifs sur-
rounding DNA sequences involved in gene conversion
[26] play a role in partial LOH. Such motifs include alter-
IHC analyses Figure 2
IHC analyses. A: An example of tumor with positive staining for MLH1. B: Same tumor as in A, with negative staining for 
MSH2. C: An example of tumor with negative staining for MLH1. D: Same tumor as in C, with positive staining for MLH1.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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MLPA-based LOH analyses Figure 3
MLPA-based LOH analyses. A: The MSH2/MLH1-MLPA analysis profile of healthy control DNA. B: germline del5-6 MLH1 
(SK-22 patient). C: SK-22 tumor, homozygous del5-6 of MLH1 indicating LOH at LGR. D: SK-14 germline, MSH2 del1-7. E: 
SK-14 tumor, retention of heterozygosity at LGR region. F: SK-20 germline, dup5-6 MSH2. G: SK-20 tumor, retention of het-
erozygosity at LGR region. Arrows, deleted/duplicated exons; asterisk, LOH.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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SNP sequencing-based LOH analyses Figure 4
SNP sequencing-based LOH analyses. A: Germline DNA of SK-14 at the c.1759+107A>G (Intron11, MSH2), reverse 
sequencing. B: SK-14 tumor DNA showing LOH at the c.1759+107A>G (Intron11, MSH2), reverse sequencing. C: Germline 
DNA of SK-20 at the c.1277-118G>A (Intron7, MSH2), forward orientation. D: SK-20 tumor DNA showing LOH at the 
c.1277-118G>A (Intron7, MSH2). E: Germline DNA of SK-22 at the c.1-93G>A (Promotor, MLH1), forward orientation. F: 
SK-22 tumor DNA showing LOH at the c.1-93G>A (Promotor, MLH1). G and H: An example of DNA sequencing profiles of 
paired germline and tumor DNA presenting no LOH at the c.1277-118G>A (Intron7, MSH2) in the tumor. Note: LOH was 
calculated as described in Methods.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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nating purine and pyrimidine or polypurine and polypy-
rimidine tracts, minisatellite sequences, and chi-like
sequences, all of which are present in the MLH1  and
MSH2  genes. The only two chi sequences (5'-GCT-
GGTGG-3') present within the MLH1 gene, as well as the
(TA)12(T)21  tract known as BAT-21, are coincidentally
located in the region that we confined to the initiating
point of the putative gene-conversion event in the SK-22
tumor (blue colored box in Figure 5). The regions of the
MSH2 gene that we confined to the initiating points of the
gene-conversion events in the SK-14 and SK-20 tumors are
rich of polypyrimidine tracts (blue colored box in Figure
6). The Alu sequences, which are abundant in both MMR
genes, are also considered to play a role in gene conver-
sion; however, their action is attributed mainly to interlo-
cus, rather than interallelic, gene-conversion events [26].
Understanding the nature of the second, i.e. somatic, hit
in the respective MMR gene may be crucial for the under-
standing of cancer initiation in HNPCC patients. Interest-
ingly, only in the case of SK-22 carrying an exon 5-6 del of
the MLH1 gene, has the wild-type sequence been replaced
by the mutated sequence encompassing a deletion of
exons 5 and 6 and resulting in a homozygous alteration in
the tumor. This LOH event should clearly lead to a com-
plete inactivation of the MLH1 gene in the tumor which is
in correlation with MSI and IHC findings. In the remain-
ing two cases of MSH2 mutation, it is difficult to distin-
guish which allele served as the 'donor' (unaltered) and
which as the 'acceptor' (altered). Since the replaced region
does not harbor a genomic rearrangement observed in the
germline, the role of such a 'second hit' in tumorigenesis
remains unclear. Nevertheless, in one tumor (SK-20) that
could be analyzed by MSI and IHC, presumably MMR
inactivation had occurred as demonstrated by the pres-
ence of high level MSI (MSI-H) and loss of MSH2 expres-
sion. It cannot be excluded that the gene conversion-
mediated sequence homogenization at several SNPs plays
a role in tumorigenesis. Another explanation might be the
presence of a 'third hit', which is difficult to fully assess in
tumor-derived DNA. Clearly, future studies on larger sets
of HNPCC patients with various types of mutations are
needed to confirm the occurrence of partial LOH events in
the MMR genes of HNPCC tumors and to elucidate the
mechanism by which they arise and their roles in tumori-
genesis.
Conclusion
In conclusion, given that LGRs of the MSH2 gene appear
to be frequent in Slovakian HNPCC families, we recom-
Schematic representation of partial LOH in the MLH1 gene Figure 5
Schematic representation of partial LOH in the MLH1 gene. A: The structure of the MLH1 gene with 19 exons (open 
boxes numbered 1-19). Exon and intron (solid line) sizes are drawn approximately to scale. B: The scheme of two MLH1 alleles 
(a1, a2) in the tumor of patient SK-22 displaying LOH at SNP marker c.1-93G>A, homozygous del5-6 (LOH), and retention of 
heterozygosity at the microsatellite marker, D3S1611, located in intron 12. MinCT, minimal converted tract; MaxCT, maximal 
converted tract; the initiating point of putative gene conversion can lie anywhere within the blue colored box; question mark 
indicates that extension of MaxCT remains unknown. Note: The term 'initiating point' is not used in the sense to indicate 
direction of gene conversion.BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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mend beginning mutational screening in this population
with the MSH2/MLH1-MLPA kit. We have discovered par-
tial LOH events at mutated genes in tumors from the
MLH1/MSH2  large genomic rearrangement carriers. To
the best of our knowledge, this finding is novel. For the
fine mapping of conversion tracts in these genes, a large
set of heterozygous markers is essential. Our results also
extend the limited knowledge of the role of gene conver-
sion in cancer.
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Schematic representation of partial LOHs in the MSH2 gene Figure 6
Schematic representation of partial LOHs in the MSH2 gene. A: The structure of the MSH2 gene with 16 exons 
(open boxes numbered 1-16). Exon and intron (solid line) sizes are drawn approximately to scale. B: The scheme of two MSH2 
alleles (a1, a2) in the tumor of patient SK-14 displaying retention of heterozygosity (no LOH) at del1-7 (dotted line) and LOH 
at SNP markers c.1511-91G>T, c.1511-9A>T, c.1661+12G>A, and c.1759+107A>G. C: The scheme of two MSH2 alleles (a1, 
a2) in the tumor of patient SK-20 displaying retention of heterozygosity (no LOH) at dup5-6 (presumably tandemly arranged) 
and LOH at SNP markers c.211+9C>G, c.211+98C>T, both in intron 1, and c.1277-118G>A in intron 7. MinCT, minimal con-
verted tract; MaxCT, maximal converted tract; the initiating point of putative gene conversion can lie anywhere within the blue 
colored box; question mark indicates that extension of MaxCT and MinCT remains unknown. Note: The term 'initiating point' 
is not used in the sense to indicate direction of gene conversion; LOH status in the SK-20 tumor (C panel) at the c.211+9C>G 
and c.211+98C>T loci has been observed previously [28].BMC Cancer 2009, 9:405 http://www.biomedcentral.com/1471-2407/9/405
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